港股生物科技公司昭衍新药(06127)股价周四盘中出现大涨,截至收盘涨幅达9.39%。
回顾公司最新一期财报,昭衍新药去年实现营收9.31亿港元,但同期出现1.86亿港元净亏损。尽管如此,多家机构对该股仍给予较高评级,其中约43%机构给予"买入"评级,43%机构给予"持有"评级,反映出市场对公司长期发展前景保持乐观预期。
分析人士指出,昭衍新药目前股价大涨或与市场对其未来发展前景充满信心有关。目前还未有官方消息透露公司出现重大利好,但机构评级显示,投资者和分析师认为公司在生物科技行业具备一定竞争优势,预计未来将会扭亏为盈并取得长期增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.